comprehensive -WSS

comprehensive

author：entertainment 2025-08-24 23:09:54 - browse：92525

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Weight loss drugs aren’t covered by Obamacare. That may change

explore

hotspot

WSS

With Wegovy coverage, Medicare patients may face high costs

Testing GLP

As AI regulations shape up, health tech startups beg for clarity

WATCH: Why do our ears pop?

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Pregnancy ages women, but effects reverse after delivery

leisure time

comprehensive

explore

Peter Hotez and the public health issue of online harassment

Pfizer, Moderna say biotech, pharma drug development is a sprint

State Dept. review finds Biden bears some blame for Afghanistan failures

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

In Memoriam: Notable people who died in 2023

MD Anderson's Padmanee Sharma responds to research credit suit

Guidelines to prevent youth baseball injuries need more muscle

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Bright Health sells Medicare Advantage business to Molina

Asbestos ban is immediate, but health effects will linger for decades

knowledge

New CMS data security rules will hurt Medicare, Medicaid research

U.K. officials, researchers try to ease path for bespoke genetic treatments

Abridge raises $150m as clinical notes automation market heats up

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Reporting on presidential health from Reagan to Trump and Biden

hotspot

explore

hotspot

hotspot